| Autor: |
Pandey, Nilesh, Kaur, Harpreet, Chorawala, Mehul R, Anand, Sumit Kumar, Chandaluri, Lakshmi, Butler, Megan, Aishwarya, Richa, Gaddam, Shiva J., Shen, Xinggui, Alfaidi, Mabruka, Wang, Jian, Zhang, Xiaolu, Beedupalli, Kavitha, Bhuiyan, Md. Shenuarin, Nobel Bhuiyan, Mohammad Alfrad, Buchhanolla, Prabandh, Rai, Prashant, Shah, Rahul, Chokhawala, Himanshu, Jordan, J. Dedrick, Magdy, Tarek, Orr, A Wayne, Stokes, Karen Y, Rom, Oren, Dhanesha, Nirav |
| Zdroj: |
Blood Advances; 20240101, Issue: Preprints |
| Abstrakt: |
Venous thromboembolic events are significant contributors to morbidity and mortality in patients with stroke. Neutrophils are among the first cells in the blood to respond to stroke and are known to promote deep vein thrombosis (DVT). Integrin α9 is a transmembrane glycoprotein, highly expressed on neutrophils and stabilizes neutrophil adhesion to activated endothelium via vascular cell adhesion molecule 1 (VCAM-1). Nevertheless, the causative role of neutrophil integrin α9 in post-stroke DVT remains unknown. Here, we found higher neutrophil integrin α9 and plasma VCAM-1 levels in humans and mice with stroke. Using mice with embolic stroke, we observed enhanced DVT severity in a novel model of post-stroke DVT. Neutrophil-specific integrin α9 deficient mice (α9fl/flMrp8Cre+/−) exhibited a significant reduction in post-stroke DVT severity along with decreased neutrophils and citrullinated histone H3 in thrombi. Unbiased transcriptomics indicated that α9/VCAM-1 interactions induced pathways related to neutrophil inflammation, exocytosis, NF-κB signaling, and chemotaxis. Mechanistic studies revealed that integrin α9/VCAM-1 interactions mediate neutrophil adhesion at the venous shear rate, promote neutrophil hyperactivation, increase phosphorylation of extracellular signal-regulated kinase (ERK), and induce endothelial cell apoptosis. Using pharmacogenomic profiling, virtual screening, and in vitro assays, we identified macitentan as a potent inhibitor of integrin α9/VCAM-1 interactions and neutrophil adhesion to activated endothelial cells. Macitentan reduced DVT severity in control mice with and without stroke, but not in α9fl/flMrp8Cre+/−mice, suggesting that macitentan improves DVT outcomes by inhibiting neutrophil integrin α9. Collectively, we uncovered a previously unrecognized and critical pathway involving the α9/VCAM-1 axis in neutrophil hyperactivation and DVT. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
